E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
gastrointestinal stromal tumors |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10051066 |
E.1.2 | Term | Gastrointestinal stromal tumour |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the preliminary efficacy of nilotinib in pretreated patients with unresectable or metastatic gastrointestinal stromal tumors. Efficacy is defined as stable disease (SD), partial response (PR) or complete response (CR) during the first 4 months according to RECIST criteria. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the time to response (SD, PR or CR) based on RECIST criteria. To evaluate the time to tumor progression based on RECIST criteria. To evaluate duration of response based on RECIST criteria. To evaluate progression free survival (PFS) during the first 4 months based on RECIST criteria of the patients who were included due to an intolerability of a prior treatment. To evaluate overall survival (OS). To evaluate the safety and tolerability of nilotinib as measured by rate and severity of adverse events. To evaluate the population pharmacokinetics of nilotinib. To compare RECIST and Choi criteria for response and time-to-event variables. To provide patients with unresectable or metastatic gastrointestinal stromal tumors showing progression with nilotinib until registration of the drug for this disease. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Age ≥ 18 years Histologically confirmed diagnosis of GIST that is unresectable and/or metastatic and therefore not amenable to surgery or combined modality with curative intent prior to or at Visit 1. Radiologically confirmed disease progression during imatinib therapy at a dose of at least 400 mg daily and/or radiologically confirmed disease progression during sunitinib therapy OR documented intolerance (defined above in population) to imatinib and/or sunitinib. (Patients with prior additional investigational treatment of GIST prior to study entry can be included.) At least one measurable site of disease on CT/MRI as defined by RECIST criteria (see Post Text Supplement 3 for details). The scans should not be older than approximately 2 weeks. New scans are only required as baseline scans if they are older than approximately 2 weeks. WHO Performance Status of 0, 1 or 2. Patients should have the following laboratory values (≥ LLN (lower limit of normal) or corrected to within normal limits with supplements prior to the first dose of study medication): - Potassium ≥ LLN, - Magnesium ≥ LLN, - Phosphorus ≥ LLN, Total calcium (corrected for serum albumin) ≥ LLN. |
|
E.4 | Principal exclusion criteria |
Prior treatment with nilotinib. Treatment with any cytotoxic and/or investigational cytotoxic drug ≤ 4 weeks (6 weeks for nitrosurea or mitomycin C) prior to Visit 1. Prior or concomitant malignancies requiring active treatment other than GIST with the exception of previous or concomitant basal cell skin cancer, previous cervical carcinoma in situ. Impaired cardiac function at visit 1 any one of the following: - LVEF < 45% or below the institutional LLN range (whichever is higher) as determined by echocardiogram at Visit 1. - Complete left bundle branch block. - Use of a ventricular paced cardiac pacemaker. - Congenital long QT syndrome or family history of long QT syndrome. - History of or presence of significant ventricular or atrial tachyarrhythmias. - Clinically significant resting bradycardia (< 50 beats per minute). - QTc > 450 msec on screening ECG (using the QTcF formula). If QTc > 450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient rescreened for QTc. - Right bundle branch block plus left anterior hemiblock, bifascicular block. - Myocardial infarction within 12 months prior to Visit 1. - Other clinically significant heart disease (e.g., unstable angina, congestive heart failure or uncontrolled hypertension). Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol e.g. impairment of gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of the study drugs, uncontrolled diabetes. Use of therapeutic coumarin derivatives (i.e. warfarin, acenoucumarol, phenprocoumon). Patients who have undergone major surgery ≤ 2 weeks prior to Visit 1 or who have not recovered from side effects of such surgery. Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation < 2 weeks prior to Visit 1 or who have not recovered from side effects of such therapy. A history of noncompliance to medical regimens or inability or unwillingness to return for scheduled visits. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy variable of this study will be the rate of patients showing complete response (CR), partial response (PR) or stable disease (SD) during the first four months according to RECIST criteria |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 30 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |